These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 28730335)

  • 1. Clinical and prognosis value of the CIMP status combined with MLH1 or p16
    Saadallah-Kallel A; Abdelmaksoud-Dammak R; Triki M; Charfi S; Khabir A; Sallemi-Boudawara T; Mokdad-Gargouri R
    Med Oncol; 2017 Aug; 34(8):147. PubMed ID: 28730335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
    Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
    Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients.
    Fu T; Liu Y; Li K; Wan W; Pappou EP; Iacobuzio-Donahue CA; Kerner Z; Baylin SB; Wolfgang CL; Ahuja N
    Oncotarget; 2016 Dec; 7(52):86480-86489. PubMed ID: 27880934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
    Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
    Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.
    Fu T; Pappou EP; Guzzetta AA; Jeschke J; Kwak R; Dave P; Hooker CM; Morgan R; Baylin SB; Iacobuzio-Donahue CA; Wolfgang CL; Ahuja N
    Clin Cancer Res; 2012 Sep; 18(17):4743-52. PubMed ID: 22825585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subsets of microsatellite-unstable colorectal cancers exhibit discordance between the CpG island methylator phenotype and MLH1 methylation status.
    Kim JH; Rhee YY; Bae JM; Kwon HJ; Cho NY; Kim MJ; Kang GH
    Mod Pathol; 2013 Jul; 26(7):1013-22. PubMed ID: 23370766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer.
    Kawakami K; Ruszkiewicz A; Bennett G; Moore J; Grieu F; Watanabe G; Iacopetta B
    Br J Cancer; 2006 Feb; 94(4):593-8. PubMed ID: 16421593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.
    Bae JM; Kim JH; Kwak Y; Lee DW; Cha Y; Wen X; Lee TH; Cho NY; Jeong SY; Park KJ; Han SW; Lee HS; Kim TY; Kang GH
    Br J Cancer; 2017 Apr; 116(8):1012-1020. PubMed ID: 28278514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer.
    Wong JJ; Hawkins NJ; Ward RL; Hitchins MP
    Mod Pathol; 2011 Mar; 24(3):396-411. PubMed ID: 21102416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP.
    Ogino S; Kawasaki T; Kirkner GJ; Yamaji T; Loda M; Fuchs CS
    Mod Pathol; 2007 Jan; 20(1):15-22. PubMed ID: 17086168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.
    Kawasaki T; Ohnishi M; Nosho K; Suemoto Y; Kirkner GJ; Meyerhardt JA; Fuchs CS; Ogino S
    Mod Pathol; 2008 Mar; 21(3):245-55. PubMed ID: 18204436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
    Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
    BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
    J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer.
    Shigeyasu K; Nagasaka T; Mori Y; Yokomichi N; Kawai T; Fuji T; Kimura K; Umeda Y; Kagawa S; Goel A; Fujiwara T
    PLoS One; 2015; 10(6):e0130409. PubMed ID: 26121593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
    Ogino S; Brahmandam M; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
    Neoplasia; 2006 Jun; 8(6):458-64. PubMed ID: 16820091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.